|
Dear PMS Families and CureSHANK supporters,
From new initiatives and partnerships to fundraisers and people, we are busier than ever at CureSHANK. We’ve increased our social media content to keep you up-to-date, and with so much news to share with you, we’ve decided to send CureSHANK Community News updates on a monthly basis, starting with this one!
In this issue, we’ll tell you about a milestone hire for our CureSHANK team, key takeaways from our second annual Phelan-McDermid Syndrome Drug Development Symposium (PMSDDS), surprising findings from our study of genetic testing labs, project news, and more. Let’s get started!
With hope and gratitude,
The CureSHANK Team
| | CureSHANK Appoints First Chief Scientific Officer | | | | |
We are thrilled to announce that we've reached a groundbreaking milestone with the appointment of our first Chief Scientific Officer, Dr. Ayan Ghoshal.
A highly accomplished translational neuroscientist with over a decade of experience in central nervous system (CNS) drug discovery and biomarker development, Ayan has successfully led translational research programs at prestigious research institutions and biotech organizations, including the Vanderbilt Center for Neuroscience Drug Discovery, the Stanley Center for Psychiatric Research at the Broad, Sunovion, and most recently, Biogen, where he spearheaded translational strategy for multiple rare neurodevelopmental programs.
With expertise across rare neurodevelopmental, neuropsychiatric, and neurological disorders, Ayan is passionate about bridging the gap between preclinical science and clinical impact. His innovative work has significantly advanced biomarker strategy and therapeutic development across modalities from small molecules and biologics to gene therapies and antisense oligonucleotides (ASOs).
CureSHANK’s mission is singular: to accelerate drug development for SHANK3-related disorders. Bringing Ayan on board supercharges that mission. He will maximize the impact of CureSHANK’s work through close alignment with industry and regulatory standards, identification and seeding of scientifically sound, operationally viable programs, and expanding the pipeline of high-impact programs faster and more effectively than ever before.
| | | 2025 PMS Drug Development Symposium: Highlights | | |
We held our second annual Phelan-McDermid Syndrome Drug Development Symposium (PMSDDS) June 25 and 26 at the Biomedical Research Park in Barcelona, Spain. CureSHANK co-founder and president Geraldine Bliss, along with PMS Association president Norma Alhambra opened the symposium with PMS parent stories from Sandra Robert, Kendra Hagedus, and Tom Giles.
The two-day event featured a rich scientific program spanning basic and translational research, clinical outcome measures, biomarkers, and updates on active commercial and non-commercial clinical trials, and a session on European trial readiness and infrastructure, emphasizing outcome measures and expanding patient registry efforts.
Key details emerging from the symposium include:
-
Biomarkers: Prof. Dr. Tobias Böckers (Ulm University) demonstrated measurable SHANK3 levels in peripheral blood mononuclear cells (PBMCs)—reduced in both SHANK3 knockout (KO) mice and PMS patients—supporting its potential as a fluid biomarker. Beta-synuclein was elevated in patients and KO mice, with data showing it could normalize with treatment, suggesting promise as a treatment response biomarker.
-
License-Free SHANK3 Knockout (KO) Mice: Ana Mignorance (Chief of Translational Science, CureSHANK) announced the successful generation of license-free SHANK3 KO mice (Ex4–22del model), which will be available from OzGene in late 2025. CureSHANK also announced a partnership with InnoSer for baseline phenotyping and high-quality preclinical testing services for PMS therapeutics. More information is available here.
-
Outcome Measures: Antonio Persico (University of Modena and Reggio Emilia) and Alex Kolevzon (Icahn School of Medicine at Mount Sinai, Developmental Synaptopathies Consortium; DSC) shared advances in the understanding of outcome measures, including the development of the SAND scale for sensory assessment. Alex also announced an update on the development of a new behavioral scale, created from the DSC natural history data and funded by the CureSHANK Biomarker & Outcome Measures Consortium in alignment with the CureSHANK-funded PMS disease concept model. Several talks focused on understanding regression in PMS as a key area for drug development.
-
Pipeline Updates: Jaguar Therapeutics announced that they have dosed a second patient in the JAG201 trial with no adverse events, and aims to launch a pivotal trial in 2027. Dr. Elizabeth Berry-Kravis (Rush University Medical Center) shared positive Phase 2 results from Neuren, with Phase 3 planned for fall 2025.
| | | |
The symposium concluded with a CureSHANK awards ceremony to honor the following contributions to and advances in PMS research:
-
The Company of the Year award was presented to PYC Therapeutics for announcing SHANK3 antisense oligonucleotides (ASO) therapy with plans to launch a clinical program in 2026.
-
Lab of the Year honors went to Dr. Tobias Böckers for foundational work on PMS biology and therapeutic discovery.
-
Our Investigator of the Year was Dr. Elizabeth Berry-Kravis, in recognition of her leadership in clinical research, challenging assumptions, and expanding her expertise to PMS-focused trials.
| | | The symposium fostered collaboration among clinicians, scientists, and industry leaders across the U.S. and Europe, and was followed by a two-day scientific conference hosted by the Spanish PMS Association for parents and families. | | | | |
JAG201 News: Second Patient Dosed; Third Site Added in Boston
Jaguar Gene Therapy announced today that a second pediatric patient has been dosed with JAG201 at Rush University Medical Center In Chicago, Illinois, U.S. No adverse safety events or concerns have been reported. Study enrollment is now open at three trial sites: Seaver Autism Center at Mount Sinai, Rush University and Boston Children’s Hospital.
As the program expands, Jaguar will give first consideration to patients who have participated in a PMS natural history trial, such as the Developmental Synaptopathies Consortium (DSC)’s Mapping the Genotype, Phenotype, and Natural History of Phelan McDermid Syndrome.
Please see Jaguar’s updated clinical trial FAQ for full details on participant eligibility, trial site contact information, and administration procedure.
| | | |
Ending False Negatives in Phelan-McDermid Syndrome
We know that genetic testing is important – in fact, it’s the only way to get a diagnosis of Phelan-McDermid syndrome. We and our colleagues at Neuren, BioLogic Pharma Solutions, and Seaver Autism Center recently discovered a significant flaw in the testing process: some genetic testing labs are unable to detect deletions or mutations of the SHANK3 gene, leading to underdiagnosis of PMS.
Our team examined the testing practices and workflows of 12 U.S. diagnostic laboratories with relevant testing for autism spectrum disorder (ASD), intellectual disability (ID), and developmental delay. Surprisingly, we identified critical gaps in detection of PMS-related genetic changes in nine of the 12 labs studied, finding incomplete sequencing or omission of SHANK3 from relevant panels. These omissions result in failure to identify hundreds of individuals with PMS each year.
At CureSHANK, we believe every patient has the right to understand their medical condition, including its genetic cause. Patients who undergo comprehensive genetic testing should be able to trust that the information returned to them is accurate and complete. In response to this finding, CureSHANK is in active discussions with the labs to improve the quality and coverage of genetic testing for PMS.
| |
| |
Start Genetic Steps Into the Spotlight
CureSHANK launched Start Genetic, an initiative to educate the public on the value of genetic testing and to empower families and physicians to consider genetic testing for developmental delays and unexplained medical issues.
| | | | |
On July 25, the first annual Genetic Testing Action Day, our message reached approximately 185 million people, thanks to our vigorous social media campaign, news coverage from the Associated Press, Yahoo! News, CNBC, CBS Radio Network, Substack, and Scribd, and support from program sponsors Genome Medical and GeneDX, who said, “We’re proud to sponsor Genetic Testing Action Day because we believe diagnosis is power, and that power belongs in the hands of families.”
Social media genetic testing and rare disease advocate @rarelifemom said, “Genetic testing gave us a diagnosis. Diagnosis gave us a fighting chance, opened the door to protocols, care teams, monitoring plans, and a rare disease community that gets it. If you’re on the fence — trust your gut, advocate hard, and know that answers can save lives.”
On the heels of our initial success, CureSHANK plans to expand the Start Genetic movement and secure a robust community of program sponsors. You can follow our updates and progress on Start Genetic social media channels Facebook, Instagram, LinkedIn, YouTube, TikTok, and X.
| | CureSHANK Launching PMS Burden of Illness Study | | | | CureSHANK will launch the first ever Burden of Illness study for Phelan-McDermid syndrome, beginning this month. Led by CureSHANK and conducted by Broadstreet Health Economics and Outcomes Research, the study will gather data from families, health insurance claims, clinical experts, and other sources. | | | In addition to direct medical costs, the study will also integrate indirect costs, such as loss in labor market earnings, productivity, the caregiver economic burden, and costs related to nonmedical care. The study outcomes will help us quantify the true economic impact of PMS, support value propositions for new therapies, and inform market access strategies. | |
Race for Research: A Recap
Our Race for Research fundraising campaign hit the ground running - literally - with U.K.-based PMS parent Tom Giles’ quest to complete nine ultramarathons in nine days (spoiler alert: he did it!), raising money, PMS awareness, and drawing a broader global audience to CureSHANK along the way. To date, the campaign has raised more than $70,000, with plans already in place to continue and expand it in 2026!
| | |
| |
CureSHANK Named Official Charity Partner of 2026 L.A. Marathon
We’re excited to announce that CureSHANK has been selected as an official Charity Partner for the 2026 Los Angeles Marathon, which will take place on March 8, 2026! This is a unique, high-visibility opportunity to raise PMS awareness and generate critical funding for research that brings us closer to treatments and, ultimately, a cure.
We’re currently building our CureSHANK marathon team, and we’re looking for committed runners to join us! We hope to fill these spots with people who have a passion for fitness, fundraising, and a personal connection to PMS to help amplify the importance of our cause with every mile.
| | | | |
CureSHANK marathon team members will receive:
If you’re a runner—or know someone who might be interested—we’d love to hear from you! Please contact Abby Lievense for participation details.
| | RESEARCH STUDIES & CLINICAL TRIALS | | |
At Home Sleep Study
People with PMS ages 12-19
The Lurie Center at Mass General seeks children with PMS ages 12-19 for a remote, at-home sleep study.
Participants will test a sleep headband that monitors brain activity for 3 nights.
Compensation up to $350.
Contact: 1+ (617) 917-4395
mghluriecentersleepheadbandstudy@mgb.org
Learn more
| | | |
Sensory Perception Study
People with PMS ages 11-21
Non-PMS siblings ages 11-21
Boston University is seeking people with PMS ages 11-21 and non-PMS siblings, also ages 11-21, to play GEODE, an online video game.
No travel required.
Participants will receive a $50 e-gift card.
Contact the project coordinator at geode.online.experiment@gmail.com for more information.
| | | |
ORTAS Toileting Survey
Caregivers of People with PMS
COMBINEDBrain seeks parents or caregivers of people with PMS and non-PMS siblings ages 1-6 for a simple, 20-30 minute survey on toileting abilities. No travel required.
Contact: ORTAS@combinedbrain.org for participation details.
Learn more
| | | |
Caregiver Observation Survey
Caregivers 18+ years old
The University of Rochester is seeking caregivers 18+ years old to provide insight on potentially significant neurodevelopmental symptoms. No travel required.
Contact jennifer.weinstein@chet.edu or charlotte.engebrecht@chet.rochester.edu for more information.
Learn more
| | | |
Biosample Collection
People with PMS
Non-PMS siblings
COMBINEDBrain's Biorepository Roadshow is seeking people diagnosed with SHANK3-related PMS of all ages and non-PMS siblings for online surveys and in-person sample collection. Please click here to find a date and location near you.
Contact abby@cureshank.org to confirm eligibility and enrollment.
Learn more
| | | |
JAG201 Gene Therapy Study
Children with PMS 2-9 years old
Jaguar Gene Therapy seeks children with PMS ages 2-9 years old for an open-label dose escalation study of JAG201 administered via intracerebroventricular (ICV) injection.
The study is currently recruiting participants for its study in New York City, Chicago, and Boston.
Contact a trial site listed below for detailed eligibility requirements.
Seaver Autism Center at Mount Sinai, NYC, NY
Contact: serena.cai@mssm.edu
Principal Investigator: Alex Kolevzon, MD
Rush University, Chicago, IL
Contact: giulia_dimarco@rush.edu or 312-942-9841
Principal Investigator: Elizabeth B Kravis, MD, PhD
Boston Children's Hospital, Boston, MA
Contact: anna.cronin@childrens.harvard.edu or 617-919-3499
Principal investigator: Siddharth Srivastava, MD
Learn more
| | | |
CureSHANK News & Events, Delivered to You
We're sharing the news and information that matters to you! Customize your CureSHANK email preferences with this short form.
| | | | |